Abstract
Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Current Protein & Peptide Science
Title: Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases
Volume: 11 Issue: 8
Author(s): E. C.Y. Toh, N. L. Huq, S. G. Dashper and E. C. Reynolds
Affiliation:
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Abstract: Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Export Options
About this article
Cite this article as:
C.Y. Toh E., L. Huq N., G. Dashper S. and C. Reynolds E., Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557646
DOI https://dx.doi.org/10.2174/138920310794557646 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry SALL4: Engine of Cell Stemness
Current Gene Therapy Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?
Current Organic Chemistry